The proportion of strong PD-L1 (TPS ≥ 50%) expression in our study was 24% and higher than that of a previous study (9.9% in EGFR-mutated lung adenocarcinoma) [23]. The gene discussed is EGFR; the disease is lung adenocarcinoma.